A patient developed tongue pain and swelling, perioral rash, and itchy intermittent hand rash one day after taking naproxen three days ago, and did not improve with cetirizine (Reactine); is this likely a fixed drug eruption and what is the appropriate outpatient management?

This is likely a delayed hypersensitivity reaction to naproxen, possibly fixed drug eruption (FDE), but the mucosal involvement (tongue swelling) raises concern for a more serious reaction requiring immediate discontinuation and close monitoring for progression to Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).

Clinical Assessment

The presentation is concerning but not classic for FDE alone. While naproxen is among the most common causes of FDE, particularly affecting the lips and perioral area 1, 2, the combination of tongue pain/swelling with perioral rash and hand involvement suggests a broader delayed hypersensitivity reaction that could represent:

• Fixed drug eruption (most likely given perioral distribution and timing)
• Early SJS/TEN (concerning given mucosal involvement with tongue swelling)
• Generalized maculopapular drug eruption

The timing fits a delayed T-cell mediated reaction - symptoms appearing 1 day after naproxen ingestion, which is consistent with delayed hypersensitivity reactions that occur >6 hours and often days after NSAID initiation 1.

Immediate Management

Discontinue naproxen immediately and permanently 3. The FDA labeling explicitly warns that NSAIDs can cause serious skin adverse events including SJS and TEN, which can be fatal, and states: "use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity" 3.

Red Flag Assessment - Rule Out SJS/TEN

You must actively assess for:

• Fever (prodromal symptom of SJS/TEN)
• Extent of mucosal involvement (oral, ocular, genital mucosa)
• Skin detachment or blistering (Nikolsky sign)
• Percentage of body surface area involved
• Systemic symptoms (malaise, conjunctivitis)

If ANY of these are present or develop, immediate hospital referral is mandatory 1. The guideline specifically notes that "prodromal symptoms of SJS/TEN include fever and mucosal involvement" and that NSAIDs, particularly naproxen (a propionic acid derivative), are associated with severe cutaneous adverse drug reactions 1.

Outpatient Treatment Protocol

If SJS/TEN is ruled out and reaction appears limited:

1. Systemic corticosteroids (not just antihistamines)

• Prednisone 0.5-1 mg/kg/day for 5-7 days with taper
• Cetirizine (Reactine) alone is insufficient for delayed hypersensitivity reactions 1

2. Topical management

• High-potency topical corticosteroids to affected areas
• Emollients for skin barrier support

3. Symptomatic relief

• Continue H1-antihistamines for pruritus (though limited efficacy in T-cell mediated reactions)
• Consider gabapentin if pruritus is severe and refractory 1

4. Close monitoring

• Daily assessment (phone or in-person) for first 3-5 days
• Watch for progression: new lesions, increased mucosal involvement, fever, blistering
• Instruct patient to return immediately if symptoms worsen

Critical Counseling Points

Permanent avoidance of naproxen is mandatory. Document this as a drug allergy in the medical record 1.

Cross-reactivity within propionic acid NSAIDs is possible but NOT universal. The guidelines note that "cross-reactivities within the same chemical class although not universal (e.g., lack of cross-reactivity between ibuprofen and naproxen reported for FDE) are well described" 1. Research confirms selective hypersensitivity to naproxen with tolerance to other propionic acids (ibuprofen, ketoprofen) has been documented 4, 5.

For future pain management:

• Acetaminophen is the safest first choice (different mechanism, no COX inhibition)
• If NSAID needed, choose from a different chemical class:
  • Celecoxib (COX-2 selective) - safest NSAID alternative 1
  • Diclofenac (acetic acid class) - but note higher association with severe reactions 1
  • Avoid all propionic acids (ibuprofen, ketoprofen, flurbiprofen) until formal allergy testing

Do NOT rechallenge with naproxen. The guideline explicitly states: "for severe reactions, avoidance without rechallenge within that class is recommended. This is due to the potential recurrence of a severe drug hypersensitivity that cannot be well predicted with current testing approaches" 1.

Allergy Referral

Refer to allergist/immunologist for:

• Formal diagnosis confirmation (patch testing on residual lesions if FDE suspected 1, 6)
• Cross-reactivity assessment with other NSAIDs via controlled oral provocation testing
• Documentation of safe NSAID alternatives

Patch testing to naproxen on previous FDE sites has variable sensitivity 1, 6, and oral provocation testing remains the gold standard but should only be performed in supervised settings 4, 5, 6.

Common Pitfall

Do not assume this is simple urticaria or immediate hypersensitivity - the delayed onset (1 day after ingestion) and mucosal involvement indicate T-cell mediated pathology, not IgE-mediated allergy. This requires different management and has different implications for cross-reactivity 1.

1113342